How These Generic Drugs Stocks are Faring? -- Patheon, Momenta Pharma, Diplomat Pharmacy, and Karyopharm Therapeutics

NEW YORK, October 26, 2016 /PRNewswire/ --

On Tuesday, the NASDAQ Composite ended the trading session at 5,283.40, down 0.50%; the Dow Jones Industrial Average edged 0.30% lower, to finish at 18,169.27; and the S&P 500 closed at 2,143.16, down 0.38%. This morning, Stock-Callers.com looks at the performance of the following Generic Drugs stocks: Patheon Holdings Cooperatief U.A. (NYSE: PTHN), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), Diplomat Pharmacy Inc. (NYSE: DPLO), and Karyopharm Therapeutics Inc. (NASDAQ: KPTI). Download the free research reports on these stocks today:

http://stock-callers.com/registration

Patheon  

On Tuesday, shares in Amsterdam, the Netherlands-based Patheon Holdings Cooperatief U.A. ended the session 4.25% lower at $27.50 with a total volume of 305,078 shares traded. Shares of Patheon have gained 10.00% in the previous three months. Shares of the Company, which provides outsourced pharmaceutical development and manufacturing services, are trading at a PE ratio of 29.60. The stock is trading 3.38% below its 50-day moving average and 0.79% below its 200-day moving average. Moreover, shares of the Company have a Relative Strength Index (RSI) of 38.80. See our free and comprehensive research report on PTHN at:

http://stock-callers.com/registration/?symbol=PTHN

Momenta Pharma  

Cambridge, Massachusetts headquartered Momenta Pharmaceuticals Inc.'s stock finished Tuesday's session 0.59% lower at $11.80 with a total volume of 291,921 shares traded. Over the last one month and the previous three months, Momenta Pharmaceuticals' shares have advanced 1.37% and 0.77%, respectively. Shares of the Company, which focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases, are trading above its 200-day moving average by 7.71%. Momenta Pharmaceuticals' stock has an RSI of 47.36.

On October 11^th, 2016, research firm Barclays upgraded the Company's stock rating from 'Equal Weight' to 'Overweight'. The research firm also revised upwards its previous target price from $13 to $19. MNTA free research report PDF is just a click away at:

http://stock-callers.com/registration/?symbol=MNTA

Diplomat Pharmacy  

Flint, Michigan headquartered Diplomat Pharmacy Inc.'s stock edged 0.24% lower, to close the day at $28.88. The stock recorded a trading volume of 345,997 shares. Shares of Diplomat Pharmacy, which stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers, have gained 15.38% in the past one year. The Company's shares are trading 4.77% and 7.40% below its 50-day and 200-day moving averages, respectively. Additionally, the stock traded at a PE ratio of 44.36 and has an RSI of 50.12. Sign up for your complimentary report on DPLO at:

http://stock-callers.com/registration/?symbol=DPLO

Karyopharm Therapeutics  

On Tuesday, shares in Newton, Massachusetts headquartered Karyopharm Therapeutics Inc. recorded a trading volume of 165,727 shares. The stock ended the day 0.35% lower at $8.45. Karyopharm Therapeutics' stock has gained 10.17% in the last three months. The Company is trading above its 200-day moving average by 5.36%. Furthermore, shares of Karyopharm Therapeutics, which focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases, have an RSI of 45.12. Register for free on Stock-Callers.com and download the latest research report on KPTI at:

http://stock-callers.com/registration/?symbol=KPTI

--

Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://stock-callers.com/legal-disclaimer/

CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number:  +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA